Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV): Journal of the European Academy of Dermatology and Venereology

P. Joly, B. Horvath, Α. Patsatsi, S. Uzun, R. Bech, S. Beissert, R. Bergman, P. Bernard, L. Borradori, M. Caproni, F. Caux, G. Cianchini, M. Daneshpazhooh, D. De, M. Dmochowski, K. Drenovska, J. Ehrchen, C. Feliciani, M. Goebeler, R. GrovesC. Guenther, S. Hofmann, D. Ioannides, C. Kowalewski, R. Ludwig, Y.L. Lim, B. Marinovic, A.V. Marzano, Jr. Mascaró J.M., D. Mimouni, D.F. Murrell, C. Pincelli, C.P. Squarcioni, M. Sárdy, J. Setterfield, E. Sprecher, S. Vassileva, K. Wozniak, S. Yayli, G. Zambruno, D. Zillikens, M. Hertl, E. Schmidt

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations. © 2020 European Academy of Dermatology and Venereology
Original languageEnglish
Pages (from-to)1900-1913
Number of pages14
JournalJ. Eur. Acad. Dermatol. Venereol.
Volume34
Issue number9
DOIs
Publication statusPublished - 2020

Keywords

  • azathioprine
  • corticosteroid
  • dapsone
  • desmoglein 1
  • desmoglein 3
  • envoplakin
  • immunosuppressive agent
  • mycophenolate mofetil
  • mycophenolic acid
  • prednisolone
  • prednisone
  • rituximab
  • Article
  • body surface
  • consultation
  • corticosteroid therapy
  • enzyme linked immunosorbent assay
  • histopathology
  • human
  • immunofluorescence microscopy
  • immunosuppressive treatment
  • medical history
  • monitoring
  • patient information
  • patient scheduling
  • pemphigus foliaceus
  • pemphigus vulgaris
  • physical examination
  • practice guideline
  • priority journal
  • relapse
  • remission

Fingerprint

Dive into the research topics of 'Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV): Journal of the European Academy of Dermatology and Venereology'. Together they form a unique fingerprint.

Cite this